Frank R. Brennan

UCB Pharma (United Kingdom) — United Kingdom

Medicine · Health Sciences

29h-index3.3kcitations80works4.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(20), T-cell and B-cell Immunology(14), Cell Adhesion Molecules Research(13), Biosimilars and Bioanalytical Methods(13), CAR-T cell therapy research(12)

Publications80 total

FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient Safety
Regulatory Toxicology and Pharmacology·2026
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
mAbs·2025· 10 citedOpen Access
Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5′- and 3′ ends
Cell Reports·2025· 2 citedOpen Access
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Science Advances·2025· 6 citedOpen Access
Assessing the impact and risk of immunomodulatory compounds on pregnancy
Journal of Reproductive Immunology·2025· 5 citedOpen Access
Multi-omics and biochemical reconstitution reveal CDK7-dependent mechanisms controlling RNA polymerase II function at gene 5’- and 3’-ends
2025Open Access
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)
Clinical Pharmacology & Therapeutics·2024· 11 citedOpen Access
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics
Drug Discovery Today·2022· 7 citedOpen Access
Non-Clinical Safety Evaluation of Immunomodulatory Biological Therapeutics for the Treatment of Immune-Mediated Diseases
2021· 2 cited
Homily Sixteenth Sunday in Ordinary Time Sunday 19 July 2020
2020
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
Clinical Pharmacology & Therapeutics·2020· 31 cited
Integration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development Paradigms
International Journal of Toxicology·2019· 11 citedOpen Access
Monoclonal Antibodies for Immune System-Mediated Diseases
2019
Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia
International Immunopharmacology·2018· 16 cited
Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions
Communications Biology·2018· 25 citedOpen Access
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration
mAbs·2018· 110 citedOpen Access
Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges
Regulatory Toxicology and Pharmacology·2018· 18 cited
Current Strategies in the non-clinical safety assessment of biologics: New Targets, New Molecules, New Challenges (A report of the 2016 Annual US BioSafe General Membership meeting)
The Novartis Repository (Novartis)·2018
Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions
Scientific Reports·2017· 47 citedOpen Access
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Science Translational Medicine·2017· 195 cited
page 1 of 4Next →

Frequent Co-authors

Tibor T. Glant(10), Katalin Mikecz(9), W D Hamilton(8), Andrea Kießling(6), Trevor Bellaby(5), Edit I. Buzás(5), Gordon Dougan(4), Louis Christodoulou(4), Bryan Smith(4), Tim D. Jones(4), Gabriela Negroiu(4), Jay Tibbitts(4), Jennifer Sims(3), Zoë Hindle(3), Steven N. Chatfield(3), Mark Milton(3), Kevin Greenslade(3), Jan‐Ingmar Flock(3), Linda B. Gilleland(3), John Staczek(3)